Financial Indicators and Analyst Sentiment for Aevi Genomic Medicine Inc. (GNMX)

    Publicly-traded company Aevi Genomic Medicine Inc. (NASDAQ:GNMX) had a closing price of $0.13 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $4.58, this means that the stock is underpriced by 97.16%. In the past 52 weeks the company’s stock price has moved within the range of $0.11 to $1.31.

    This particular stock’s 5-day moving average is 0.13, its 20-day moving average is 0.13 and its 100-day moving average is 0.17. Aevi Genomic Medicine Inc. (GNMX) currently has 65.60M shares outstanding, which means that its market capitalization is $8.66M.

    The Details: Aevi Genomic Medicine Inc. (GNMX) Financial Health

    We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Aevi Genomic Medicine Inc. Return on Assets is -202.80%.

    What Does Wall Street Say about Company?

    When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for GNMX is Hold. Out of 1 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 1 rated it hold, and 0 rated it a Buy.

    Understanding Profitability at Aevi Genomic Medicine Inc. (GNMX)

    A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Aevi Genomic Medicine Inc., for the quarter ending on 09/2019, the company posted EPS of -0.05. The average estimate of Wall Street analysts had projected -0.05.

    Wall Street analysts, on average, are forecasting the company’s EPS to be -0.16, compared to -0.22 reported in the same quarter last year.